Suppr超能文献

一位炎症性肠病患者接受生物治疗的二十年历程。

Twenty years of biological therapy in an patient with IBD.

作者信息

Mak Wing Yan, Segal Jonathan P, Hart Ailsa

机构信息

IBD Unit, St. Mark's Hospital, Harrow, UK.

出版信息

BMJ Case Rep. 2018 Jan 23;2018:bcr-2017-221994. doi: 10.1136/bcr-2017-221994.

Abstract

This interesting case is the first to our knowledge to report outcomes of a patient with Crohn's disease (CD) treated with the biological drug, infliximab, for around 20 years. The case highlights the positive effect of long-term use of infliximab in achieving and maintaining remission in a patient with CD.In this case, loss of response to infliximab was not dependent on length of exposure to the drug. It also appeared that infliximab was still efficacious after drug holidays, which can be especially important around times of pregnancy. Of interest, 'loss of response' to infliximab occurred at one particular time point. The drug was then reintroduced at a later date, which gave the patient clinical benefit. This case suggests that in some situations infliximab can be reintroduced in patients with previous 'loss of response'.Importantly, in this case, Infliximab had no major adverse effects during the 20 years follow-up.

摘要

据我们所知,这个有趣的病例是首例报告使用生物药物英夫利昔单抗治疗克罗恩病(CD)约20年的患者的治疗结果。该病例突出了长期使用英夫利昔单抗对一名克罗恩病患者实现并维持缓解的积极作用。在这个病例中,对英夫利昔单抗反应丧失并不取决于药物暴露时长。看起来英夫利昔单抗在停药期后仍有效,这在孕期尤其重要。有趣的是,对英夫利昔单抗的“反应丧失”发生在一个特定时间点。之后在晚些时候重新使用该药物,给患者带来了临床益处。这个病例表明,在某些情况下,之前出现过“反应丧失”的患者可以重新使用英夫利昔单抗。重要的是,在这个病例中,英夫利昔单抗在20年的随访期间没有出现重大不良反应。

相似文献

本文引用的文献

3
Safety of infliximab in 10 years of clinical practice.10 年临床实践中 infliximab 的安全性。
Eur J Gastroenterol Hepatol. 2011 Jul;23(7):603-6. doi: 10.1097/MEG.0b013e3283479125.
6
Perianal Crohn's disease: overview.肛周克罗恩病:概述
Dig Liver Dis. 2007 Oct;39(10):957-8. doi: 10.1016/j.dld.2007.07.152. Epub 2007 Aug 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验